Alexion Pharmaceuticals (ALXN) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
227.0mn → 222.0mn diluted shares since FY16. Part of EPS growth is the shrinking denominator. Watch net income too.
−31.0% YoY in FY20 · 1.8% of revenue.
$0.5B returned vs $2.9B of FCF in FY20. Buybacks covered by cash flow.
10¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Over this window: gross 91.6% → 90.9%. Net margin 9.9% is more than double the sector median.
| Line item | TTM † | FY20 | FY19 | FY18 | FY17 | FY16 | YoY | CAGR 16→20 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 6,261.6 | 6,069.9 | 4,991.1 | 4,131.2 | 3,551.1 | 3,084.1 | ▲21.6% | +18.4% |
Cost of revenue | 567.2 | 553.5 | 394.5 | 374.3 | 454.2 | 258.3 | ▲40.3% | +21.0% |
Gross profit | 5,694.4 | 5,516.4 | 4,596.6 | 3,756.9 | 3,096.9 | 2,825.8 | ▲20.0% | +18.2% |
Research & development | 1,284.4 | 1,002.9 | 881.9 | 1,913.4 | 878.4 | 757.2 | ▲13.7% | +7.3% |
Selling, general & admin | 1,422.9 | 1,399.9 | 1,261.1 | 1,111.8 | 1,094.4 | 953.0 | ▲11.0% | +10.1% |
Total operating expenses | 5,121.4 | 4,884.1 | 2,476.2 | 3,487.3 | 2,469.5 | 2,158.4 | ▲97.2% | +22.6% |
Operating incomefeeds ROC rank | 573.0 | 632.3 | 2,120.4 | 269.6 | 627.4 | 667.4 | ▼70.2% | −1.3% |
Other income, net | −65.0 | −63.3 | 58.4 | −27.4 | −79.6 | −91.2 | — | — |
Pretax income | 508.0 | 569.0 | 2,178.8 | 242.2 | 547.8 | 576.2 | ▼73.9% | −0.3% |
Income tax | −27.0 | −34.4 | −225.5 | 164.6 | 104.5 | 176.8 | ▲84.7% | — |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 535.0 | 603.4 | 2,404.3 | 77.6 | 443.3 | 399.4 | ▼74.9% | +10.9% |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 3.08 | 2.72 | 10.70 | 0.35 | 1.97 | 1.76 | ▼74.6% | +11.5% |
Diluted shares (mn) | 222.60 | 222.00 | 224.80 | 224.50 | 225.40 | 227.00 | ▼1.2% | −0.6% |
| Margins | ||||||||
Gross margin73rd pct in Healthcare | 90.9% | 90.9% | 92.1% | 90.9% | 87.2% | 91.6% | ▼1.2pp | −0.7pp |
Operating margin | 9.2% | 10.4% | 42.5% | 6.5% | 17.7% | 21.6% | ▼32.1pp | −11.2pp |
Net margin74th pct in Healthcare | 8.5% | 9.9% | 48.2% | 1.9% | 12.5% | 13.0% | ▼38.2pp | −3.0pp |
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Alexion Pharmaceuticals' revenue last fiscal year?
Alexion Pharmaceuticals reported revenue of $6,069.9M in fiscal 2020, up 21.6% from fiscal 2019.
What was Alexion Pharmaceuticals' net income?
Alexion Pharmaceuticals reported net income of $603.4M in fiscal 2020, a net margin of 9.9%.

